Search research articles
Contact Us
Filters
Showing results (121-130 of 173) with videos related to
Page
of 18
Sort By:
Gynecologic Oncology
|
October 4, 2021
Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer
Elizabeth M Swisher, Rebecca S Kristeleit, Amit M Oza, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 24, 2019
Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria
Ignacio Matos, Juan Martin-Liberal, Alonso García-Ruiz, et al.
The Lancet. Oncology
|
June 22, 2014
Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial
Bradley J Monk, Andrés Poveda, Ignace Vergote, et al.
Gynecologic Oncology
|
July 30, 2020
Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial
Ana Oaknin, Claire F Friedman, Lynda D Roman, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 3, 2022
EMPOWER CERVICAL-1: Effects of cemiplimab versus chemotherapy on patient-reported quality of life, functioning and symptoms among women with recurrent cervical cancer
Ana Oaknin, Bradley J Monk, Ignace Vergote, et al.
JAMA Network Open
|
November 2, 2023
Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors: A Nonrandomized Controlled Trial
Thierry André, Dominique Berton, Giuseppe Curigliano, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
June 9, 2021
Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3
Andrew R Clamp, Domenica Lorusso, Amit M Oza, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
May 1, 2023
ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer - Update 2023
David Cibula, Maria Rosaria Raspollini, François Planchamp, et al.
Cancer Cell
|
April 16, 2015
AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas
Moshe Elkabets, Evangelos Pazarentzos, Dejan Juric, et al.
Gynecologic Oncology
|
October 20, 2023
Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100
Jonathan A Ledermann, Ronnie Shapira-Frommer, Alessandro D Santin, et al.
Page
of 18
Search research articles
Search
Showing results (121-130 of 173) with videos related to
Sort By:
Page
of 18
Gynecologic Oncology
|
October 4, 2021
Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer
Elizabeth M Swisher, Rebecca S Kristeleit, Amit M Oza, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 24, 2019
Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria
Ignacio Matos, Juan Martin-Liberal, Alonso García-Ruiz, et al.
The Lancet. Oncology
|
June 22, 2014
Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial
Bradley J Monk, Andrés Poveda, Ignace Vergote, et al.
Gynecologic Oncology
|
July 30, 2020
Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial
Ana Oaknin, Claire F Friedman, Lynda D Roman, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 3, 2022
EMPOWER CERVICAL-1: Effects of cemiplimab versus chemotherapy on patient-reported quality of life, functioning and symptoms among women with recurrent cervical cancer
Ana Oaknin, Bradley J Monk, Ignace Vergote, et al.
JAMA Network Open
|
November 2, 2023
Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors: A Nonrandomized Controlled Trial
Thierry André, Dominique Berton, Giuseppe Curigliano, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
June 9, 2021
Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3
Andrew R Clamp, Domenica Lorusso, Amit M Oza, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
May 1, 2023
ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer - Update 2023
David Cibula, Maria Rosaria Raspollini, François Planchamp, et al.
Cancer Cell
|
April 16, 2015
AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas
Moshe Elkabets, Evangelos Pazarentzos, Dejan Juric, et al.
Gynecologic Oncology
|
October 20, 2023
Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100
Jonathan A Ledermann, Ronnie Shapira-Frommer, Alessandro D Santin, et al.
Page
of 18